AWM
CMPX icon

Avior Wealth Management’s Compass Therapeutics CMPX Stock Holding History

Avior Wealth Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-16
Closed -$31 – 2553
2024
Q1 		$31 Buy
+16
New +$28 ﹤0.01% 3596

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Avior Wealth Management's CMPX Position: Q2 2024 in Review

Avior Wealth Management sold out of Compass Therapeutics (CMPX) in Q2 2024, closing a stake of 16 shares — an estimated $31 sold.

Avior Wealth Management first reported a position in CMPX in Q1 2024 and held it in 1 quarter. The position peaked at $31 in Q1 2024. 82 funds tracked by Wall St. Rank hold CMPX as of Q2 2024.

  • Avior Wealth Management reported no remaining Compass Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 16 Compass Therapeutics shares in Q2 2024, an estimated $31.
  • Avior Wealth Management first reported a position in Compass Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Compass Therapeutics position peaked at $31 in Q1 2024.
  • 82 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.